SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-008756
Filing Date
2020-07-30
Accepted
2020-07-30 18:46:22
Documents
62
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20200630x10q.htm   iXBRL 10-Q 1800572
2 EX-10.2 crvs-20200630ex102381d6b.htm EX-10.2 67900
3 EX-31.1 crvs-20200630ex31108cc97.htm EX-31.1 11879
4 EX-31.2 crvs-20200630ex312408384.htm EX-31.2 11817
5 EX-32.1 crvs-20200630ex321e7a679.htm EX-32.1 11818
6 GRAPHIC crvs-20200630x10q006.jpg GRAPHIC 68772
  Complete submission text file 0001558370-20-008756.txt   6312169

Data Files

Seq Description Document Type Size
7 EX-101.SCH crvs-20200630.xsd EX-101.SCH 36163
8 EX-101.CAL crvs-20200630_cal.xml EX-101.CAL 48582
9 EX-101.DEF crvs-20200630_def.xml EX-101.DEF 110075
10 EX-101.LAB crvs-20200630_lab.xml EX-101.LAB 363820
11 EX-101.PRE crvs-20200630_pre.xml EX-101.PRE 251869
12 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20200630x10q_htm.xml XML 1071485
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 201061445
SIC: 2834 Pharmaceutical Preparations